Alteration of BAFF and APRIL in the cerebrospinal fluid based on the therapeutic response in primary central nervous system B-cell lymphoma

Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
Junji IkedaYoshiki Sekijima

Abstract

We evaluated the cerebrospinal fluid (CSF) levels of the B-cell activating factor of the tumor necrosis factor family (BAFF) and A proliferation-inducing ligand (APRIL) in two cases of primary central nervous system B-cell lymphoma (PCNSBL) before and after treatment. One patient achieved clinical remission, and demonstrated decrease in the CSF levels of both BAFF and APRIL after treatment. Meanwhile, the other patient with insufficient therapeutic response showed increase in the BAFF levels despite decrease in APRIL levels. This report suggests that the combination of BAFF and APRIL levels could be useful in estimating the therapeutic efficacy in treating PCNSBL as reliable CSF markers.

References

Jun 6, 2003·Cytokine & Growth Factor Reviews·Fabienne Mackay, Christine Ambrose
Mar 18, 2009·BMC Cancer·Jérôme MoreauxBernard Klein
May 21, 2013·Cytokine & Growth Factor Reviews·Fabien B VincentFabienne Mackay
Dec 20, 2018·Annals of Clinical and Translational Neurology·Hironori MizutaniYukio Ando

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.